Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease

ClinicalTrials.gov ID

NCT02652741

Lead Sponsor

Ethicare GmbHINDUSTRY

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 2Phase 3

Enrollment

50Estimated

Last Update Posted

Jan 12, 2016Estimated

Start Date

Jan 2016

Primary Completion Date

Jun 2017Estimated

Completion Date

Jun 2017Estimated

Official Title

Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease

Brief Summary

Paediatric clinical trial in 50 children, from newborn to less than 6 years of age, suffering from heart failure due to congenital heart disease, to obtain paediatric pharmacokinetic and pharmacodynamic data of enalapril and its active metabolite enalaprilat while treated for 8 weeks with enalapril in form of Orodispersible Minitablets (ODMTs), to describe the dose exposure in this patient population.

Detailed Description

This clinical trial is one of three clinical trials of the European Commission (FP7)-funded "LENA" (Labeling of Enalapril from Neonates to Adolescents) project: 50 children with heart failure due to congenital heart disease (LENA-Work Package (WP)09 Trial), and 50 children with heart failure due to dilated cardiomyopathy (LENA-WP08 Trial) get treated with an optimal dose of enalapril ODMTs for up to 8 weeks after thorough, individualised titration and get invited to join the 10 months Safety Follow-up Study (LENA-WP10 Trial).

In this WP09 Trial children from age of newborn to less than 6 years, naive to enalapril treatment or switched from an Angiotensin-Converting-Enzyme (ACE)-Inhibitor pre-treatment, receive an Initial Dose to investigate the reaction over 8 hours before a decision on the first dose level is made. Always up to 7 days later a next higher dose is given at the hospital, the patient is supervised for 4 and then always 2 hours before a decision on the prescribed dose for the next dosing period is made. In this study a target dose similar to the adult target dose (20 mg enalapril in a 70 year old adult result in 0.282 mg/kg/day enalapril) is defined. Enalapril ODMTs of 0.25 mg and 1 mg strength are available to allow for an individual dose titration scheme.

Weight-dependently, pharmacokinetic (PK) and pharmacodynamic (PD) data are collected once in a full PK/PD day over 12, respectively 6 hours, and single PK/PD samples at each Dose Titration Visit and each bi-weekly Study Control Visit until the Last Visit after 8 weeks of treatment. Blood pressure and renal monitoring is performed at each visit before deciding on the dose level for the next treatment period.

Pharmacogenomics and metabolomics exploratory studies are added as a sub-study to better understand the underlying disease, its progression as well as the impact of the ACE-inhibition on cardiac outcome and renal function.

• Heart Failure
• Congenital Heart Disease

• Enalapril Orodispersible Minitablet

Ages Eligible for Study

Child (0-17)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

Patients fulfilling the following Inclusion Criteria can be enrolled:

• Age from birth to less than 6 years.
• Male and female patients.
• Weight greater than 2.5 kg.
• Diagnosis of heart failure due to congenital heart disease requiring after-load reduction by drug therapy.
• Subjects may be naïve to ACE-Inhibitors.
• Subjects already on ACE-Inhibitors willing to switch to enalapril Orodispersible Minitablets.
• Patient and/or parent(s)/legal representative provided written informed consent and assent from the patient according to national legislation and as far as achievable from the child.

Exclusion Criteria:

Patients fulfilling any of the following Exclusion Criteria cannot be enrolled into this trial:

• Neonates if born < 37 weeks of gestation.

• Severe heart failure and/or end stage heart failure precluding introduction or continuation of ACE-Inhibitor.

• Too low blood pressure, e.g. ˂P5

• Uncorrected primary obstructive valvular disease, or significant systemic ventricular outflow obstruction, dilated restrictive or hypertrophic cardiomyopathy.

• Uncorrected severe peripheral stenosis of large arteries including severe coarctation of the aorta.

• Severe renal impairment with serum creatinine >2x Upper Limit of Normal (ULN) (according to the hospital's test methodology)

• History of angioedema.

• Hypersensitivity to ACE-Inhibitors.

• Concommitant medication:

  • Dual ACE-Inhibitor therapy
  • Renin inhibitors
  • Angiotensin II antagonists
  • Non-Steroidal Anti-Inflammatory Drugs (including ibuprofen) except for aspirin and paracetamol

• Already enrolled in an interventional trial with an investigational drug, unless no interference with the current study can be shown.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Ethicare GmbHINDUSTRY

m.dalinghaus@erasmusmc.nl+3110-7040704

h.breur@umcutrecht.nl+ 31 8875 540 02

milica.bajcetic@udk.bg.ac.rs38 1112060716

michael.burch@gosh.nhs.uk+44 020 7405 9200

• Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy

  NCT02652728

  Unknown statusInterventionalPhase 2Phase 3Updated Jan 12, 2016
• Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril

  NCT02654678

  Unknown statusInterventionalPhase 2Phase 3Updated Jan 13, 2016
• Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)

  NCT06659393

  RecruitingObservationalUpdated Apr 13, 2026
• Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

  NCT02678312

  CompletedInterventionalPhase 2Phase 3Updated Feb 10, 2023
• Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network

  NCT00113087

  CompletedInterventionalPhase 3Updated Sep 28, 2010
• Study of Drug Therapy for Pediatric Heart Failure

  NCT06039540

  Unknown statusObservationalUpdated Sep 15, 2023